Methionine-induced hepatic coma in dogs.

Area of Science:

• Biochemistry
• Gastroenterology
• Neurology

Background:

• Oral methionine is generally safe in healthy individuals.
• Elevated ammonia levels are associated with neurological dysfunction in liver disease.
• Portacaval shunts alter ammonia metabolism.

Purpose of the Study:

• To investigate the comatogenic effects of oral methionine in dogs with portacaval shunts.
• To explore the role of ammonia and methanethiol in methionine-induced coma.
• To understand the mechanisms underlying hepatic encephalopathy.

Main Methods:

• Administration of oral methionine to normal dogs and dogs with portacaval shunts.
• Monitoring of ammonia and methanethiol levels.
• Clinical and electroencephalographic assessment of induced coma.

Main Results:

• Oral methionine induced coma in portacaval shunt dogs, particularly with high ammonia levels (>1,000 mug/100 ml).
• Methionine-induced coma mimicked other canine coma models clinically and electroencephalographically.
• Methanethiol release from the bowel was implicated, with its comatogenic effect amplified by ammonia.

Conclusions:

• Methionine's comatogenic action in portacaval shunt dogs is ammonia-dependent and likely mediated by methanethiol.
• A synergistic effect between ammonia and methanethiol may contribute to hepatic encephalopathy.
• Further research into ammonia and methanethiol reduction therapies is warranted.